Zimmer Biomet Holdings, Inc. (ZBH)
USD 105.86
(-2.04%)
USD 105.86
(-2.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.44 Billion USD | 17.49% |
| 2022 | 2.21 Billion USD | 1.8% |
| 2021 | 2.16 Billion USD | 11.35% |
| 2020 | 969.7 Million USD | -22.68% |
| 2019 | 2.39 Billion USD | 4.4% |
| 2018 | 1.05 Billion USD | -22.1% |
| 2017 | 1.84 Billion USD | 15.61% |
| 2016 | 1.78 Billion USD | 24.79% |
| 2015 | 2.33 Billion USD | 39.75% |
| 2014 | 1.78 Billion USD | -17.23% |
| 2013 | 1.4 Billion USD | -1.13% |
| 2012 | 1.42 Billion USD | 15.99% |
| 2011 | 1.38 Billion USD | -15.86% |
| 2010 | 1.25 Billion USD | 4.93% |
| 2009 | 1.35 Billion USD | 10.03% |
| 2008 | 1.4 Billion USD | -4.78% |
| 2007 | 1.36 Billion USD | 14.74% |
| 2006 | 1.36 Billion USD | 1.54% |
| 2005 | 1.35 Billion USD | 22.34% |
| 2004 | 1.1 Billion USD | 50.45% |
| 2003 | 644.8 Million USD | 72.6% |
| 2002 | 426.2 Million USD | 56.86% |
| 2001 | 248.3 Million USD | -6.66% |
| 2000 | 291.1 Million USD | 15.06% |
| 1999 | 253 Million USD | 6.75% |
| 1998 | 237 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 578.7 Million USD | 2.25% |
| 2024 Q3 | 535.5 Million USD | -17.48% |
| 2024 Q1 | 564.9 Million USD | -9.97% |
| 2023 Q4 | 675.9 Million USD | 24.45% |
| 2023 Q2 | 598.2 Million USD | -1.92% |
| 2023 Q1 | 609.9 Million USD | 34.22% |
| 2023 Q3 | 543.1 Million USD | -9.21% |
| 2023 FY | - USD | 17.49% |
| 2022 FY | - USD | 1.8% |
| 2022 Q2 | 525.5 Million USD | 24.47% |
| 2022 Q1 | 422.2 Million USD | 33.73% |
| 2022 Q3 | 491.4 Million USD | -6.49% |
| 2022 Q4 | 454.4 Million USD | -7.53% |
| 2021 Q2 | 556.4 Million USD | -3.54% |
| 2021 Q3 | 531.1 Million USD | -4.55% |
| 2021 Q1 | 576.8 Million USD | 31.96% |
| 2021 Q4 | 315.7 Million USD | -40.56% |
| 2021 FY | - USD | 11.35% |
| 2020 Q3 | 593.7 Million USD | 1280.7% |
| 2020 Q1 | 461.4 Million USD | -12.23% |
| 2020 Q2 | 43 Million USD | -90.68% |
| 2020 Q4 | 437.1 Million USD | -26.38% |
| 2020 FY | - USD | -22.68% |
| 2019 FY | - USD | 4.4% |
| 2019 Q1 | 608.1 Million USD | 34.89% |
| 2019 Q2 | 533.6 Million USD | -12.25% |
| 2019 Q3 | 492 Million USD | -7.8% |
| 2019 Q4 | 525.7 Million USD | 6.85% |
| 2018 Q4 | 450.8 Million USD | -10.5% |
| 2018 FY | - USD | -22.1% |
| 2018 Q1 | 671 Million USD | -7.32% |
| 2018 Q2 | 605.8 Million USD | -9.72% |
| 2018 Q3 | 503.7 Million USD | -16.85% |
| 2017 Q2 | 701.4 Million USD | -3.36% |
| 2017 FY | - USD | 15.61% |
| 2017 Q4 | 724 Million USD | 12.88% |
| 2017 Q3 | 641.4 Million USD | -8.55% |
| 2017 Q1 | 725.8 Million USD | 22.07% |
| 2016 Q2 | 600.2 Million USD | 2.77% |
| 2016 Q3 | 653.5 Million USD | 8.88% |
| 2016 Q4 | 594.6 Million USD | -9.01% |
| 2016 FY | - USD | 24.79% |
| 2016 Q1 | 584 Million USD | 178.63% |
| 2015 Q4 | 209.6 Million USD | -62.44% |
| 2015 Q1 | 430.9 Million USD | 76.96% |
| 2015 Q3 | 558 Million USD | 25.2% |
| 2015 FY | - USD | 39.75% |
| 2015 Q2 | 445.7 Million USD | 3.43% |
| 2014 Q4 | 243.5 Million USD | -39.35% |
| 2014 FY | - USD | -17.23% |
| 2014 Q3 | 401.5 Million USD | -6.63% |
| 2014 Q2 | 430 Million USD | -3.97% |
| 2014 Q1 | 447.8 Million USD | -4.89% |
| 2013 Q2 | 428.3 Million USD | 1.85% |
| 2013 Q1 | 420.5 Million USD | 19.73% |
| 2013 Q4 | 470.8 Million USD | 33.07% |
| 2013 Q3 | 353.8 Million USD | -17.39% |
| 2013 FY | - USD | -1.13% |
| 2012 FY | - USD | 15.99% |
| 2012 Q3 | 372.8 Million USD | -13.26% |
| 2012 Q2 | 429.8 Million USD | 0.19% |
| 2012 Q1 | 429 Million USD | 49.58% |
| 2012 Q4 | 351.2 Million USD | -5.79% |
| 2011 Q1 | 408.8 Million USD | -37.38% |
| 2011 FY | - USD | -15.86% |
| 2011 Q4 | 286.8 Million USD | -23.21% |
| 2011 Q3 | 373.5 Million USD | 3.41% |
| 2011 Q2 | 361.2 Million USD | -11.64% |
| 2010 Q3 | 365.3 Million USD | 10.03% |
| 2010 Q1 | 381.6 Million USD | -22.36% |
| 2010 Q2 | 332 Million USD | -13.0% |
| 2010 FY | - USD | 4.93% |
| 2010 Q4 | 652.8 Million USD | 78.7% |
| 2009 Q1 | 373.4 Million USD | 4.45% |
| 2009 FY | - USD | 10.03% |
| 2009 Q4 | 491.5 Million USD | 46.02% |
| 2009 Q3 | 336.6 Million USD | -8.9% |
| 2009 Q2 | 369.5 Million USD | -1.04% |
| 2008 Q1 | 408 Million USD | -8.46% |
| 2008 Q2 | 400.8 Million USD | -1.76% |
| 2008 Q4 | 357.5 Million USD | 6.46% |
| 2008 Q3 | 335.8 Million USD | -16.22% |
| 2008 FY | - USD | -4.78% |
| 2007 Q2 | 386.3 Million USD | 0.08% |
| 2007 Q3 | 359.5 Million USD | -6.94% |
| 2007 FY | - USD | 14.74% |
| 2007 Q1 | 386 Million USD | 0.49% |
| 2007 Q4 | 445.7 Million USD | 23.98% |
| 2006 Q4 | 384.1 Million USD | 21.63% |
| 2006 FY | - USD | 1.54% |
| 2006 Q3 | 315.8 Million USD | -7.61% |
| 2006 Q1 | 333.1 Million USD | -11.05% |
| 2006 Q2 | 341.8 Million USD | 2.61% |
| 2005 FY | - USD | 22.34% |
| 2005 Q1 | 336.5 Million USD | 6.32% |
| 2005 Q2 | 341.3 Million USD | 1.43% |
| 2005 Q3 | 301.6 Million USD | -11.63% |
| 2005 Q4 | 374.5 Million USD | 24.17% |
| 2004 Q1 | 258.1 Million USD | -8.25% |
| 2004 Q3 | 262.3 Million USD | -2.64% |
| 2004 Q2 | 269.4 Million USD | 4.38% |
| 2004 FY | - USD | 50.45% |
| 2004 Q4 | 316.5 Million USD | 20.66% |
| 2003 Q2 | 134.7 Million USD | 10.52% |
| 2003 FY | - USD | 72.6% |
| 2003 Q3 | 422.76 Million USD | 171.22% |
| 2003 Q1 | 122 Million USD | 20.31% |
| 2003 Q4 | 193.7 Million USD | -33.73% |
| 2002 Q4 | 117.7 Million USD | 12.63% |
| 2002 FY | - USD | 56.86% |
| 2002 Q1 | 93.8 Million USD | 21.5% |
| 2002 Q2 | 103.4 Million USD | 17.48% |
| 2002 Q3 | 98.1 Million USD | -5.17% |
| 2001 Q3 | 50.8 Million USD | -18.0% |
| 2001 FY | - USD | -6.66% |
| 2001 Q2 | 68.9 Million USD | 9.89% |
| 2001 Q1 | 62.7 Million USD | -20.33% |
| 2001 Q4 | 60.2 Million USD | 36.64% |
| 2000 Q2 | 71.9 Million USD | 10.96% |
| 2000 Q1 | 64.8 Million USD | 0.0% |
| 2000 FY | - USD | 15.06% |
| 2000 Q4 | 78.7 Million USD | 11.79% |
| 2000 Q3 | 70.4 Million USD | -2.09% |
| 1999 FY | - USD | 6.75% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 76.595% |
| Allurion Technologies Inc. | -69.03 Million USD | 3647.537% |
| Artivion, Inc. | 38.14 Million USD | -6320.481% |
| Avanos Medical, Inc. | 53.2 Million USD | -4503.195% |
| Butterfly Network, Inc. | -124.84 Million USD | 2061.568% |
| Butterfly Network, Inc. | -124.84 Million USD | 2061.568% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 502.604% |
| Boston Scientific Corporation | 3.45 Billion USD | 29.079% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | 16604.246% |
| CONMED Corporation | 182.18 Million USD | -1244.176% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | -38.544% |
| Paragon 28, Inc. | -36.61 Million USD | 6788.425% |
| Glaukos Corporation | -82.11 Million USD | 3082.245% |
| Globus Medical, Inc. | 418.23 Million USD | -485.526% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 14454.631% |
| Integer Holdings Corporation | 282.05 Million USD | -768.223% |
| Medtronic plc | 9.05 Billion USD | 72.958% |
| Nevro Corp. | -78.31 Million USD | 3227.187% |
| Owlet, Inc. | -27.48 Million USD | 9008.654% |
| Penumbra, Inc. | 111.99 Million USD | -2086.596% |
| Vicarious Surgical Inc. | -69.19 Million USD | 3639.282% |
| Smith & Nephew plc | 979 Million USD | -150.143% |
| Sonendo, Inc. | -54.76 Million USD | 4571.407% |
| STERIS plc | 1.41 Billion USD | -73.385% |
| Stryker Corporation | 5.16 Billion USD | 52.541% |
| Vapotherm, Inc. | -34.35 Million USD | 7227.805% |